Glaxo reveals promising lab results for new British-made vaccine that could target multiple Covid variants – with 50m doses on order from the UK | WHAT REALLY HAPPENED

Glaxo reveals promising lab results for new British-made vaccine that could target multiple Covid variants – with 50m doses on order from the UK

British drugmaker GlaxoSmithKline said its new Covid vaccine has produced good results in initial laboratory tests, with human trials expected to begin this year and ministers set to order up to 50 million doses of the jab.

The mRNA technology at the heart of the vaccine could be used to create a so-called multivalent jab that would be designed to protect against several Covid variants, GSK and German partner CureVac said.

A first version of the vaccine developed by the German company had failed in large-scale trials. The latest trials were conducted in collaboration with Harvard and involved macaque monkeys being jabbed with either the original vaccine or a new version, known as CV2CoV.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA